Posts

Showing posts with the label real-world

covid: vaccine effectiveness in outpatient and inpatient setting

  An article assessed vaccine effectiveness for both mRNA vaccines and the J&J one against symptomatic Covid infection, including hospitalization, admission to the ICU, or ambulatory care in an emergency department or urgent care clinic (see  covid vaccine effectiveness in outpt and inpt setting nejm2021 in dropbox, or DOI: 10.1056/NEJMoa2110362 )   Details:  -- 41,552 hospital admissions to 187 hospitals and 21,522 visits to 221 emergency departments or urgent care clinics, from January 1 through June 22, 2021, for adults at least 50 years old with a Covid-like illness     -- this analysis was done through the CDC’s VISION Network, in collaboration with seven US healthcare systems having a total of 187 hospitals and research centers with integrated medical, laboratory, and vaccination records     -- Covid-like illness was a defined as a clinical diagnosis of acute respiratory illness, or signs and symptoms that have been ...

Covid: Moderna/ J&J work ag delta virus and other variants; delta surging

  A recent preprint, pre-peer-reviewed article suggested that the Moderna mRNA vaccine should work against all four of the major SARS-CoV-2 variants, per measured neutralizing antibody titers (see  covid moderna ag delta  in dropbox, or  https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1.full.pdf  ), based on company-sponsored study    Details:  -- sera from eight patient one week following dose 2 of the Moderna mRNA-1273 vaccine  were  evaluated for neutralizing antibody response to a variety of variants of concern: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2)      -- additionally, tests were done for the following variants of interest: B.1.1.526 (now called Iota, first identified in the US), A.23.1 (first identified in Uganda), B.1.525 (now called Eta, first identified in Nigeria), and A.VOI.V2  (first identified in Angola)  -- see the above link to the text for mor...